Literature DB >> 22009216

Prostate-specific membrane antigen: a new potential prognostic marker of osteosarcoma.

Chao Zeng1, Zun-Fu Ke, Zheng Yang, Zhuo Wang, Shi-Cong Yang, Can-Qiao Luo, Lian-Tang Wang.   

Abstract

Previous studies have demonstrated that the expression of prostate-specific membrane antigen (PSMA) is restricted to endothelium from tumor-associated neovasculature. But the expression of PSMA in osteosarcoma and its clinical significance are unknown. Using immunohistochemical analysis and quantum dot probes, we found that 46.7% (21/45) of the osteosarcoma showed positive staining for PSMA while no PSMA staining in osteofibrous dysplasia. The expression and localization of PSMA was confirmed by CD34 staining. More importantly, the expression of PSMA is correlated with tumor size, pulmonary metastasis and worse survival (survival rate 63.2% in the PSMA-negative group versus 36.6% in the PSMA-positive group). Thus, PSMA could be used as an independent prognostic marker for the osteosarcoma patients, and PSMA staining in tumor-associated neovasculature may be a potential target for antineovasculature-based therapy in osteosarcoma.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22009216     DOI： 10.1007/s12032-011-0089-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  22 in total

1.  Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.

Authors:  J S Horoszewicz; E Kawinski; G P Murphy
Journal:  Anticancer Res       Date:  1987 Sep-Oct       Impact factor: 2.480

2.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

Authors:  S S Chang; V E Reuter; W D Heston; N H Bander; L S Grauer; P B Gaudin
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

3.  Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value?

Authors:  J L Gala; S Loric; Y Guiot; S R Denmeade; A Gady; F Brasseur; M Heusterspreute; P Eschwège; P De Nayer; P Van Cangh; B Tombal
Journal:  Clin Cancer Res       Date:  2000-10       Impact factor: 12.531

4.  Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium.

Authors:  H Liu; P Moy; S Kim; Y Xia; A Rajasekaran; V Navarro; B Knudsen; N H Bander
Journal:  Cancer Res       Date:  1997-09-01       Impact factor: 12.701

5.  Molecular expression of PSMA mRNA and protein in primary renal tumors.

Authors:  F Dumas; J L Gala; P Berteau; F Brasseur; P Eschwège; V Paradis; B Lacour; M Philippe; S Loric
Journal:  Int J Cancer       Date:  1999-03-15       Impact factor: 7.396

6.  Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models.

Authors:  Ghanashyam D Ghadge; Barbara S Slusher; Amos Bodner; Mauro Dal Canto; Krystyna Wozniak; Ajit G Thomas; Camilo Rojas; Takashi Tsukamoto; Pavel Majer; Richard J Miller; Anna Liza Monti; Raymond P Roos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-22       Impact factor: 11.205

7.  Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase).

Authors:  R Luthi-Carter; A K Barczak; H Speno; J T Coyle
Journal:  J Pharmacol Exp Ther       Date:  1998-08       Impact factor: 4.030

8.  Expression of the prostate-specific membrane antigen.

Authors:  R S Israeli; C T Powell; J G Corr; W R Fair; W D Heston
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

9.  ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma.

Authors:  M Onda; S Matsuda; S Higaki; T Iijima; J Fukushima; A Yokokura; T Kojima; H Horiuchi; T Kurokawa; T Yamamoto
Journal:  Cancer       Date:  1996-01-01       Impact factor: 6.860

10.  Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.

Authors:  Jeffrey S Ross; Christine E Sheehan; Hugh A G Fisher; Ronald P Kaufman; Prabhjot Kaur; Karen Gray; Iain Webb; Gary S Gray; Rebecca Mosher; Bhaskar V S Kallakury
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531
View more
  6 in total

Review 1.  Prostate-specific membrane antigen as a target for cancer imaging and therapy.

Authors:  A P Kiess; S R Banerjee; R C Mease; S P Rowe; A Rao; C A Foss; Y Chen; X Yang; S Y Cho; S Nimmagadda; M G Pomper
Journal:  Q J Nucl Med Mol Imaging       Date:  2015-07-24       Impact factor: 2.346

Review 2.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236

3.  Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST.

Authors:  Birthe Heitkötter; Marcel Trautmann; Inga Grünewald; Martin Bögemann; Kambiz Rahbar; Heidrun Gevensleben; Eva Wardelmann; Wolfgang Hartmann; Konrad Steinestel; Sebastian Huss
Journal:  Oncotarget       Date:  2017-01-17

4.  18F-PSMA-1007 PET/CT uptake in multiple angiolipomas caused by PSMA expression in capillaries: a case report.

Authors:  Long Wang; Yongxiang Tang; Hongling Yin; Shuo Hu
Journal:  Transl Androl Urol       Date:  2021-02

5.  Folate hydrolase-1 (FOLH1) is a novel target for antibody-based brachytherapy in Merkel cell carcinoma.

Authors:  M K Ramirez-Fort; B Meier-Schiesser; K Lachance; S S Mahase; C D Church; M J Niaz; H Liu; V Navarro; A Nikolopoulou; D V Kazakov; E Contassot; D P Nguyen; J Sach; L Hadravsky; Y Sheng; S T Tagawa; X Wu; C S Lange; L E French; P T Nghiem; N H Bander
Journal:  Skin Health Dis       Date:  2020-11-28

6.  Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid.

Authors:  Birthe Heitkötter; Konrad Steinestel; Marcel Trautmann; Inga Grünewald; Peter Barth; Heidrun Gevensleben; Martin Bögemann; Eva Wardelmann; Wolfgang Hartmann; Kambiz Rahbar; Sebastian Huss
Journal:  Oncotarget       Date:  2018-01-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.